Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
Novartis has presented new data that demonstrated once-daily Ultibro Breezhaler (indacaterol/glycopyrronium bromide) was superior in reducing exacerbations (flare ups) and...
The GLOW 3 study investigated the effects of Seebri Breezhaler (NVA237), (glycopyrronium bromide) 50 mcg once-daily from Novartis on exercise...
Novartis announced new analyses of data for once-daily Ultibro Breezhaler (investigational QVA 149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered...
Novartis has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler...
Results of the INTENSITY study ,being a comparison of Onbrez Breezhaler (indacaterol) from Novartis with Spiriva(tiotropium)from Boehringer/Pfizer were announced in...
Novartis announced new data from the QUANTIFY study, which demonstrated the non-inferiority of Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg compared to...
Results of the first pooled analysis of GLOW1 and GLOW2 data demonstrated that patients with COPD using the Seebri Breezhaler...